Atopic Dermatitis | Incyte | INCB18424-303
Pharmaceutical Company/Sponsor:
Incyte
Code:
INCB18424-303
Title:
Topical Ruxolitinib Evaluation in Atopic Dermatitis Study 1 (TRuE AD1) - A Phase 3, Double-Blind, Randomized, 8-Week, Vehicle-Controlled Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Adolescents and Adults With Atopic Dermatitis
Type:
Interventional
Phase:
3
Condition/Disease:
Atopic Dermatitis
Intervention(s)/Treatment(s):
Drug: Ruxolitinib cream
Drug: Vehicle cream
Status:
Active, Not Recruiting
Link for Additional Information:
